EU recommends Daxas approval following FDA panel rejection

Nycomed is in luck. The European Medicines Agency today recommended approval of Daxas, the company's once-a-day pill for patients with severe COPD. The approval follows an expert FDA panel's decision earlier this month not to recommend the drug for approval. In a 10-5 vote, panelists determined the side effects of Daxas outweighed the limited improvement in lung function. The ruling was a blow to Nycomed's partner Forest Labs, which has U.S. rights to Daxas. A final FDA decision is due in May.

Nycomed says it will launch Daxas later this year once it obtains a formal approval from the European Commission. The drug's approval there could lead to an IPO for Nycomed, which has planned to go public but never provided a timetable for doing so. "Nycomed is excited about the positive opinion of the CHMP recommending approval of Daxas in the European Union. Daxas is the first in a new class of oral agents to treat this life-threatening condition, offering clinicians and patients a much needed new treatment option alongside existing inhaled therapies," said Anders Ullman, Nycomed executive vice president of R&D.

- here's Nycomed's release on the approval
- read more from Reuters

Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

Mutations in RIPK1 can cause uncontrolled cell death and inflammation, researchers discovered by studying families with an autoimmune disorder.